Laboratory Medicine ›› 2018, Vol. 33 ›› Issue (10): 958-961.DOI: 10.3969/j.issn.1673-8640.2018.10.021
Previous Articles Next Articles
Received:2017-08-22
Online:2018-10-30
Published:2018-10-23
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2018.10.021
| [1] | LICCI S.Duodenal localization of plasmablastic myeloma[J]. World J Gastrointest Pathophysiol,2017,8(2):93-95. |
| [2] | CHOI Q,KIM H K.Plasmablastic plasma cell myeloma mimicking plasmablastic lymphoma[J]. Korean J Hematol,2010,45(4):223. |
| [3] | RAJKUMAR S V,DIMOPOULOS M A,PALUMBO A, et al.International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma[J]. Lancet Oncol,2014,15(12):e538-e548. |
| [4] | SAILER M,VYKOUPIL K F,PEEST D,et al.Prognostic relevance of a histologic classification system applied in bone marrow biopsies from patients with multiple myeloma:a histopathological evaluation of biopsies from 153 untreated patients[J]. Eur J Haematol,1995,54(3):137-146. |
| [5] | MØLLER H E,PREISS B S,PEDERSEN P,et al. Clinicopathological features of plasmablastic multiple myeloma:a population-based cohort[J]. APMIS,2015,123(8):652-658. |
| [6] | BARTL R,FRISCH B,BURKHARDT R,et al.Bone marrow histology in myeloma:its importance in diagnosis,prognosis,classification and staging[J]. Br J Haematol,1982,51(3):361-375. |
| [7] | GREIPP P R,RAYMOND N M,KYLE R A,et al. Multiple myeloma:significance of plasmablastic subtype in morphological classification[J]. Blood,1985,65(2):305-310. |
| [8] | GREIPP P R,LEONG T,BENNETT J M,et al.Plasmablastic morphology-an independent prognostic factor with clinical and laboratory correlates:Eastern Cooperative Oncology Group(ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group[J]. Blood,1998,91(7):2501-2507. |
| [9] | ILIADIS A,KOLETSA T,KOSTOPOULOS I.Aberrant expression of T-cell marker CD7 in HIV negative intestinal plasmablastic lymphoma[J]. Pathology,2016,48(7):731-733. |
| [10] | AMMANNAGARI N,CELOTTO K,NEPPALLI V,et al.Anaplastic multiple myeloma:an aggressive variant with a poor response to novel therapies[J]. Clin Lymphoma Myeloma Leuk,2016,16(9):e129-e131. |
| [11] | KUMAR S,RAJKUMAR S V,KIMLINGER T,et al.CD45 expression by bone marrow plasma cells in multiple myeloma:clinical and biological correlations[J]. Leukemia,2005,19(8):1466-1470. |
| [12] | LIN O,GERHARD R,ZERBINI M C,et al.Cytologic features of plasmablastic lymphoma[J]. Cancer,2005,105(3):139-144. |
| [13] | 侯著法. Ki-67增殖指数与多发性骨髓瘤预后关系的研究[J]. 湖北民族学院学报(医学版),2004,21(4):6-8. |
| [14] | KIM D,PARK C Y,MEDEIROS B C,et al.CD19-CD45 low/-CD38 high/CDl38+ plasma cells enrich for human tumorigenic myeloma cells[J]. Leukemia,2012,26(12):2530-2537. |
| [15] | CHAIDOS A,BARNES C P,COWAN G,et al.Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma[J]. Blood,2013,121(2):318-328. |
| [16] | TCHERNONOG E,FAURIE P,COPPO P,et al.Clinical characteristics and prognostic factors of plasmablastic lymphoma patients:analysis of 135 patients from the LYSA group[J]. Ann Oncol,2017,28(4):843-848. |
| [17] | CHAN K T,CHOI M Y,LAI K K,et al.Overexpression of transferrin receptor CD71 and its tumorigenic properties in esophageal squamous cell carcinoma[J]. Oncol Rep,2014,31(3):1296-1304. |
| [18] | VEGA F,CHANG C C,MEDEIROS L J,et al.Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles[J]. Mod Pathol,2005,18(6):806-815. |
| [19] | DELECLUSE H J,ANAGNOSTOPOULOS I,DALLENBACH F,et al.Plasmablastic lymphomas of the oral cavity:a new entity associated with the human immunodeficiency virus infection[J]. Blood,1997,89(4):1413-1420. |
| [20] | CARBONE A.AIDS-related non-Hodgkin's lymphomas:from pathology and molecular pathogenesis to treatment[J]. Hum Pathol,2002,33(4):392-404. |
| [21] | AHN J S,OKAL R,VOS J A,et al.Plasmablastic lymphoma versus plasmablastic myeloma:an ongoing diagnostic dilemma[J]. J Clin Pathol,2017,70(9):775-780. |
| [22] | 陈嘉利,黎庆恩. Burkitt淋巴瘤细胞骨髓中形态学特征与组织病理学的比较分析[J]. 现代检验医杂志,2005,20(5):30-32. |
| [23] | TADDESSE-HEATH L,MELONI-EHRIG A,SCHEERLE J,et al.Plasmablastic lymphoma with MYC translocation:evidence for a common pathway in the generation of plasmablastic features[J]. Mod Pathol,2010,23(7):991-999. |
| [24] | XIAO R,CERNY J,DEVITT K,et al.MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance(MGUS)[J]. Am J Surg Pathol,2014,38(6):776-783. |
| [25] | BAHMANYAR M,QI X,CHANG H.Genomic aberrations in anaplastic multiple myeloma:high frequency of 1q21(CKS1B) amplifications[J]. Leuk Res,2013,37(12):1726-1728. |
| [26] | SETHI S,MILLER I.Plasma cell myeloma with anaplastic transformation[J]. Blood,2016,128(16):2106. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
